Medical Specialties Commons^™

Efficacy And Safety Of Covid-19 Convalescent Plasma In Hospitalized Patients: A Randomized Clinical Trial, Mila B. Ortigoza, Hyunah Yoon, Keith S. Goldfeld, Andrea B. Troxel, Johanna P. Daily, Yinxiang Wu, Yi Li, Danni Wu, Gia F. Cobb, Andrew N. Dentino

School of Medicine Publications and Presentations

Importance: There is clinical equipoise for COVID-19 convalescent plasma (CCP) use in patients hospitalized with COVID-19.

Objective: To determine the safety and efficacy of CCP compared with placebo in hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen.

Design, setting, and participants: CONTAIN COVID-19, a randomized, double-blind, placebo-controlled trial of CCP in hospitalized adults with COVID-19, was conducted at 21 US hospitals from April 17, 2020, to March 15, 2021. The trial enrolled 941 participants who were hospitalized for 3 or less days or presented 7 or less days after symptom onset and required noninvasive oxygen supplementation.

Interventions: A unit of …

Impact Of Covid-19 On Otolaryngology Literature, Yeshwant R. Chillakuru, Eleanor F. Gerhard, Timothy Shim, Samuel H. Selesnick, Lawrence R. Lustig, John H. Krouse, Ehab Y. Hanna, Timothy L. Smith, Edward W. Fisher, Joseph E. Kerschner, Ashkan Monfared

School of Medicine Publications and Presentations

Objective

To understand the effect of the COVID-19 pandemic on the volume, quality, and impact of otolaryngology publications.

Methods

Fifteen of the top peer-reviewed otolaryngology journals were queried on PubMed for COVID and non-COVID related articles from April 1, 2020 - March 31, 2021 (pandemic period) and pre-COVID articles from the year prior. Information on total number of submissions and rate of acceptance were collected from seven top-ranked journals.

Results

Our PubMed query returned 759 COVID articles, 4885 non-COVID articles, and 4200 pre-COVID articles, corresponding to a 34% increase in ENT publications during the pandemic period. Meta-analysis/reviews and miscellaneous publication …

Role Of Nutraceuticals In Covid-19 Mediated Liver Dysfunction, Mohammed Sikander, Shabnam Malik, Anyssa Rodriguez, Murali M. Yallapu, Acharan S. Narula, Sanjaya K. Satapathy, Vijian Dhevan, Subhash C. Chauhan, Meena Jaggi

School of Medicine Publications and Presentations

COVID-19 is known as one of the deadliest pandemics of the century. The rapid spread of this deadly virus at incredible speed has stunned the planet and poses a challenge to global scientific and medical communities. Patients with COVID-19 are at an increased risk of co-morbidities associated with liver dysfunction and injury. Moreover, hepatotoxicity induced by antiviral therapy is gaining importance and is an area of great concern. Currently, alternatives therapies are being sought to mitigate hepatic damage, and there has been growing interest in the research on bioactive phytochemical agents (nutraceuticals) due to their versatility in health benefits reported …

Tough Decisions During The Covid 19 Pandemic: A Frail Latino Patient, Irma Huayanay, Stephanie Luu

School of Medicine Publications and Presentations

The pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had overwhelmed the healthcare system worldwide with multiple ethical dilemmas. Several tools have been used to assess risk factors in these patients. One of them, the Clinical Frailty scale, has shown good correlation between the patient functional status and hospital stay with overall mortality. We present a case were the Clinical Frailty Scale was used to assess patient management and goals of care.

Part Ii. High-Dose Methotrexate With Leucovorin Rescue For Severe Covid-19: An Immune Stabilization Strategy For Sars-Cov-2 Induced 'Panic' Attack, Elliot M. Frohman, Nicole R. Villemarette-Pittman, Roberto A. Cruz, Reid Longmuir, Vernon Rowe, Elizabeth S. Rowe, Thomas C. Varkey, Lawrence Steinman, Scott S. Zamvil, Teresa C. Frohman

School of Medicine Publications and Presentations

Here, in Part II of a duology on the characterization and potential treatment for COVID-19, we characterize the application of an innovative treatment regimen for the prevention of the transition from mild to severe COVID-19, as well as detail an intensive immunotherapy intervention hypothesis. We propose as a putative randomized controlled trial that high-dose methotrexate with leucovorin (HDMTX-LR) rescue can abolish 'PANIC', thereby 'left-shifting' severe COVID-19 patients to the group majority of those infected with SARS-CoV-2, who are designated as having mild, even asymptomatic, disease. HDMTX-LR is endowed with broadly pleiotropic properties and is a repurposed, generic, inexpensive, and widely …